Arcus Biosciences (RCUS) Change in Account Payables (2017 - 2026)

Arcus Biosciences' Change in Account Payables history runs 10 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 200.0% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was $18.0 million, a 157.14% increase from a year earlier, with the FY2025 full-year figure at $24.0 million, up 700.0% from the prior year.
• Change in Account Payables eased to -$3.0 million in Q1 2026 per RCUS's latest filing, from $13.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $13.0 million in Q3 2025 and bottomed at -$19.0 million in Q2 2023.
• The 5-year median for Change in Account Payables is $4.0 million (2022), against an average of $2.1 million.
• Across the five-year window, Change in Account Payables jumped 1786.79% in 2022 and sank 575.0% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at $8.0 million in 2022, then sank by 75.0% to $2.0 million in 2023, then jumped by 150.0% to $5.0 million in 2024, then surged by 160.0% to $13.0 million in 2025, then plunged by 123.08% to -$3.0 million in 2026.
• Per Business Quant, the three latest RCUS Change in Account Payables figures stand at -$3.0 million (Q1 2026), $13.0 million (Q3 2025), and $8.0 million (Q2 2025).